Products in the clinic and a discovery pipeline for the future
Our current focus is on two inter-related programmes in oncology and wound healing that have significant market potential as human and animal medicines.
By diversifying and co-developing our portfolio in these two therapeutic areas for both human and animal health we:
- Leverage data from our veterinary clinical trials that are treating 'real-world' disease to provide solid proof-of-concept of our drug candidates before they move to the human clinic, significantly de-risking our human programmes; and,
- Create the opportunity to generate early, significant and repeatable revenue from the more rapid path to market of veterinary products, which we reinvest into our longer-term, higher-value human programmes.
For the future, our proprietary EcoLogic™ discovery platform provides opportunities to identify new molecular scaffolds from nature with potential applications in human and veterinary medicine.
The first of these future areas, a discovery stage programme for next generation antibiotics that target bacterial virulence, is ready to progress into development once our current clinical products are commercialised.